In addition, proton pump inhibitors can be prescribed to reduce acid reflux, which can worsen symptoms of esophageal achalasia. Antibiotics may also be prescribed to treat any bacterial infections that may be contributing to the condition. In more severe cases, surgery may be required to improve the movement of food down the esophagus. Surgical options may include esophagomyotomy, which involves cutting the muscles at the lower end of the esophagus, or a surgical procedure to remove the LES.
Esophageal achalasia is a rare neurological disorder that affects the ability of the esophagus to move food towards the stomach. The condition is characterized by the failure of the LES to relax, resulting in difficulty swallowing, chest pain, and regurgitation of food. While the exact cause of achalasia remains unknown, some studies have suggested that it may be linked to autoimmune disorders, genetic factors, or viral infections.
Recent studies have shown an increasing prevalence of esophageal achalasia globally, with a higher incidence observed in certain geographic regions such as Asia and South America. In the U.S., the estimated prevalence of achalasia is approximately 1 in 100,000 people, with a higher incidence observed in older adults.
As a result of the increasing prevalence of achalasia, there is a growing demand for drugs that can effectively treat this condition. Currently, the main treatment options for achalasia include medications, pneumatic dilation, and surgical intervention. For example, medications such as nitrates and CCBs can help to relax the LES and improve swallowing function. However, these drugs may have significant side effects and are not effective for all patients.
In recent years, new drugs such as botulinum toxin injections and peroral endoscopic myotomy (POEM) have emerged as promising treatment options for achalasia. Botulinum toxin injections can help to relax the LES and improve swallowing function, while POEM involves a minimally invasive surgical procedure that can be used to cut the muscles of the esophageal sphincter and improve swallowing function.
New product launches to flourish in the market
In 2019, EndoGastric Solutions launched EsophyX Z, a minimally invasive device that can be used to perform POEM procedures. The device allows surgeons to perform the procedure with greater precision and accuracy. In 2020, Johnson & Johnson's Ethicon division launched the HARMONIC HD 1000i Shears, a surgical device that can be used to perform POEM procedures. The device is designed to provide greater precision and control during the procedure. In 2021, Medtronic launched the Infinity Deep Brain Stimulation System for the treatment of achalasia. The device is designed to deliver electrical stimulation to the LES and improve swallowing function. In 2022, Boston Scientific launched the Crux VCF System, a minimally invasive device that can be used to perform POEM procedures. The device is designed to provide greater precision and control during the procedure.
By drug type: The esophageal achalasia drug market is divided into CCBs, Nifedipine, and other. The esophageal achalasia drug market has traditionally been divided into two main categories: CCBs and Nifedipine. CCBs are a class of medications that can help to relax the LES and improve swallowing function. Nifedipine is a type of CCB that is commonly used for the treatment of achalasia. However, in recent years, new drugs and treatments have emerged that fall outside of these traditional categories. For example, botulinum toxin injections and POEM procedures are becoming increasingly popular as treatment options for achalasia. Other emerging treatment options include surgical interventions such as laparoscopic Heller myotomy and magnetic sphincter augmentation.
By route of administration: The esophageal achalasia drug market is classified into Injectables and Oral. Injectables include botulinum toxin injections, which are administered directly into the LES to help relax the muscle and improve swallowing function. These injections are typically administered by a gastroenterologist or other trained healthcare professional using endoscopy.
Oral medications include CCBs, such as nifedipine, which can help to relax the LES and improve swallowing function. Other oral medications that may be used to treat achalasia include nitrates and anticholinergics. In addition to injectables and oral medications, other treatments and interventions for achalasia may include minimally invasive procedures such as POEM, laparoscopic Heller myotomy, and magnetic sphincter augmentation.
By distribution channel: The esophageal achalasia drug market is classified into retail pharmacies, hospital pharmacies, and online pharmacies. Retail pharmacies are the most common type of pharmacy, and they typically sell a wide range of prescription and over-the-counter medications. Patients can visit their local retail pharmacy to fill their prescriptions for medications such as CCBs or nifedipine. Hospital pharmacies, on the other hand, are located within hospitals and other medical facilities. They provide medications for inpatient and outpatient care and may have a more limited selection of medications available for purchase. Finally, online pharmacies are becoming increasingly popular as a convenient way for patients to purchase medications from the comfort of their own home. Patients can order medications such as CCBs or nifedipine online and have them delivered directly to their door.
By region: The Asia-Pacific region is a growing market for esophageal achalasia drugs, driven by several factors. One of the main drivers of the market is the increasing prevalence of esophageal achalasia in the region. This is due to factors such as aging populations, changing lifestyles, and an increased incidence of risk factors such as obesity. Another key driver of the market is the growing awareness of esophageal achalasia and its treatment options in the region. As healthcare infrastructure and education improve, patients are becoming more aware of the condition and seeking treatment for their symptoms. In addition, increasing healthcare spending in the region is expected to drive growth in the esophageal achalasia drug market. As more patients seek treatment, there is likely to be an increasing demand for effective and affordable medications.
Competitive analysis and profiles of the major players in the esophageal achalasia drug market, such as Accord Healthcare, AdvaCare Pharmaceuticals, Galderma, Merz Therapeutics, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals (U.S.) Inc. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the esophageal achalasia drug market.
Esophageal Achalasia Drug Market Report Highlights
By DRUG TYPE
By ROUTE OF ADMINISTRATION
By DISTRIBUTION CHANNEL
Key Market Players
Zydus Pharmaceuticals (USA) Inc, GALDERMA, Teva Pharmaceutical Industries Ltd., advacare pharmaceuticals, Accordhealthcare, Merz Therapeutics, Pfizer Inc.